Obesity is a complex, chronic disease affecting hundreds of millions of people across diverse populations. Recent advances in incretin biology – especially GLP-1 receptor agonists – have shifted expectations for efficacy, safety, and trial design.
But with this evolution comes new questions: How are trials adapting endpoints, comparators, and duration? What impact does obesity have on the prevalence of other systemic diseases? What does cross-population data tell us about accessibility and equity? And how will long-term outcomes, adherence, and combination therapies influence clinical practice?
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Listen now to the latest installment of Novotech’s expert podcast, exploring the rapidly evolving world of global obesity clinical trials and the transformative role of GLP-1 therapies. Bringing together Novotech’s Medical Monitor Dr. Kathryn Stecco, and Senior Therapeutic Strategy Manager Gab Silver, the podcast unpacks how IP modalities, biomarkers and the latest in GLP1 innovations are reshaping obesity treatment worldwide.
